Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Contrast-associated acute kidney injury (CA-AKI) is a common complication of procedures with
intravascular contrast. Generally, CA-AKI is defined as serum creatinine (Scr) ≥ 25 to 50% or
Scr rise around 0.3 to 0.5 mg/dl. The initial rise in SCr is typically seen within 48 to 72 h
of contrast exposure .CA-AKI has been associated with increased hospital length of stay and
excess costs. Therefore, the prevention of CA-AKI is beneficial for minimizing hospital
costs, mortality and morbidity. Till now, what is clearly beneficial in CIN is adequate
hydration before and after coronary angiography However, further measures are trialed, aiming
to reduce more morbidity and mortality. There is a great deal of publications pertaining to
the possible therapeutic interventions to avoid the ultimate outcome of complete kidney
failure. Accordingly, allopurinol has been suggested as a promising measure for the
prevention of acute kidney injury after coronary angiography through protecting the kidney by
inhibiting XO activity and blocking the generation of oxygen radicals. However, studies have
shown conflicting results. Trimetazidine is cellular anti-ischemic drug which has been shown
to protect against free radical damage due to its antioxidant activity. It has been recently
shown to decrease the risk of CIN in percutaneous coronary intervention (PCI) in some
studies. However, it is worth mentioning that studies evaluating trimetazidine under
presented patients with high estimated glomerular filtration rate (eGFR). Accordingly, Aimed
to evaluate the combination of trimetazidine with allopurinol versus using trimetazidine
alone to define the most effective strategy to be implemented in the clinical setting in
patients with diverse risk factors and normal GFR.